BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

197 related articles for article (PubMed ID: 28809741)

  • 1. Hepatitis C Virus Infection Outcomes Among Immigrants to Canada: A Retrospective Cohort Analysis.
    Cooper CL; Thavorn K; Damian E; Corsi DJ
    Ann Hepatol; 2017; 16(5):720-726. PubMed ID: 28809741
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hepatitis C virus infection characteristics and treatment outcomes in Canadian immigrants.
    Cooper CL; Read D; Vachon ML; Conway B; Wong A; Ramji A; Borgia S; Tam E; Barrett L; Smyth D; Feld JJ; Lee S;
    BMC Public Health; 2020 Sep; 20(1):1345. PubMed ID: 32883249
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Uptake and factors associated with direct-acting antiviral therapy for hepatitis C and treatment outcomes among Canadian immigrants: A retrospective cohort analysis.
    Petrosyan Y; Simmons JG; Kelly E; Cooper CL
    Can Liver J; 2022 Aug; 5(3):388-401. PubMed ID: 36133896
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluation of immigration status, race and language barriers on chronic hepatitis C virus infection management and treatment outcomes.
    Giordano C; Druyts EF; Garber G; Cooper C
    Eur J Gastroenterol Hepatol; 2009 Sep; 21(9):963-8. PubMed ID: 19318966
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Influence of female sex on hepatitis C virus infection progression and treatment outcomes.
    Corsi DJ; Karges W; Thavorn K; Crawley AM; Cooper CL
    Eur J Gastroenterol Hepatol; 2016 Apr; 28(4):405-11. PubMed ID: 26745470
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Decentralised hepatitis C testing and treatment in rural Cambodia: evaluation of a simplified service model integrated in an existing public health system.
    Zhang M; O'Keefe D; Craig J; Samley K; Bunreth V; Jolivet P; Balkan S; Marquardt T; Dousset JP; Le Paih M
    Lancet Gastroenterol Hepatol; 2021 May; 6(5):371-380. PubMed ID: 33743883
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Direct-Acting Antiviral Therapy Outcomes in Canadian Chronic Hepatitis C Telemedicine Patients.
    Cooper CL; Hatashita H; Corsi DJ; Parmar P; Corrin R; Garber G
    Ann Hepatol; 2017 November-December,; 16(6):874-880. PubMed ID: 29055923
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Interferon-based hepatitis C therapy in a safety net hospital: access, efficacy, and safety.
    Nordstrom EM; Keniston A; Baouchi F; Martinez-Camacho A
    Eur J Gastroenterol Hepatol; 2017 Jan; 29(1):10-16. PubMed ID: 27755117
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sustained Virologic Response of Patients Hospitalized Compared With Those Not Hospitalized During Treatment for Hepatitis C Virus With Direct-Acting Antivirals.
    Gentene AJ; Bell AM; Pence A; Thomas K; Jakubecz C; Stacy E; Woolf B; Guido MR; Mueller EW; Sherman KE
    Ann Pharmacother; 2021 May; 55(5):565-574. PubMed ID: 33016095
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Direct Acting Antivirals Improve HCV Treatment Initiation and Adherence Among Underserved African Americans.
    Beck KR; Kim NJ; Khalili M
    Ann Hepatol; 2018; 17(3):413-418. PubMed ID: 29735789
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Increased Risk for Hepatocellular Carcinoma Persists Up to 10 Years After HCV Eradication in Patients With Baseline Cirrhosis or High FIB-4 Scores.
    Ioannou GN; Beste LA; Green PK; Singal AG; Tapper EB; Waljee AK; Sterling RK; Feld JJ; Kaplan DE; Taddei TH; Berry K
    Gastroenterology; 2019 Nov; 157(5):1264-1278.e4. PubMed ID: 31356807
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Risk of Hepatocellular Cancer in HCV Patients Treated With Direct-Acting Antiviral Agents.
    Kanwal F; Kramer J; Asch SM; Chayanupatkul M; Cao Y; El-Serag HB
    Gastroenterology; 2017 Oct; 153(4):996-1005.e1. PubMed ID: 28642197
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Incidence of Hepatocellular Carcinoma After Direct Antiviral Therapy for HCV in Patients With Cirrhosis Included in Surveillance Programs.
    Nahon P; Layese R; Bourcier V; Cagnot C; Marcellin P; Guyader D; Pol S; Larrey D; De Lédinghen V; Ouzan D; Zoulim F; Roulot D; Tran A; Bronowicki JP; Zarski JP; Riachi G; Calès P; Péron JM; Alric L; Bourlière M; Mathurin P; Blanc JF; Abergel A; Serfaty L; Mallat A; Grangé JD; Attali P; Bacq Y; Wartelle C; Dao T; Thabut D; Pilette C; Silvain C; Christidis C; Nguyen-Khac E; Bernard-Chabert B; Zucman D; Di Martino V; Sutton A; Roudot-Thoraval F; Audureau E;
    Gastroenterology; 2018 Nov; 155(5):1436-1450.e6. PubMed ID: 30031138
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hepatitis C treatment uptake and response among human immunodeficiency virus/hepatitis C virus-coinfected patients in a large integrated healthcare system.
    Lam JO; Hurley LB; Chamberland S; Champsi JH; Gittleman LC; Korn DG; Lai JB; Quesenberry CP; Ready J; Saxena V; Seo SI; Witt DJ; Silverberg MJ; Marcus JL
    Int J STD AIDS; 2019 Jun; 30(7):689-695. PubMed ID: 31046611
    [TBL] [Abstract][Full Text] [Related]  

  • 15. HIV infection does not increase the risk of liver complications in hepatitis C virus-infected patient with advanced fibrosis, after sustained virological response with direct-acting antivirals.
    Corma-Gómez A; Morano L; Téllez F; Rivero-Juárez A; Real LM; Alados JC; Ríos-Villegas MJ; Vera-Méndez FJ; Muñoz RP; Geijo P; Macías J; Pineda JA;
    AIDS; 2019 Jun; 33(7):1167-1174. PubMed ID: 30845068
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Liver function following hepatitis C virus eradication by direct acting antivirals in patients with liver cirrhosis: data from the PITER cohort.
    Quaranta MG; Ferrigno L; Tata X; D'Angelo F; Coppola C; Ciancio A; Bruno SR; Loi M; Giorgini A; Margotti M; Cossiga V; Brancaccio G; Dallio M; De Siena M; Cannizzaro M; Cavalletto L; Massari M; Mazzitelli M; De Leo P; Laccabue D; Baiocchi L; Kondili LA
    BMC Infect Dis; 2021 May; 21(1):413. PubMed ID: 33947337
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sofosbuvir-Based Therapy in the Pre-Liver Transplant Setting: The Canadian National Experience.
    Al-Judaibi B; Thomas B; Wong P; Benmassaoud A; Chen JH; Dokus MK; Hussaini T; Bilodeau M; Burak KW; Marotta P; Yoshida EM
    Ann Hepatol; 2018; 17(3):437-443. PubMed ID: 29735784
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Liver Fibrosis in Human Immunodeficiency Virus (HIV)-Hepatitis C Virus (HCV) Coinfection Before and After Sustained Virologic Response: What Is the Best Noninvasive Marker for Monitoring Regression?
    Kronfli N; Young J; Wang S; Cox J; Walmsley S; Hull M; Cooper C; Martel-Laferriere V; Wong A; Pick N; Klein MB;
    Clin Infect Dis; 2021 Aug; 73(3):468-477. PubMed ID: 32504083
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Detection of residual HCV-RNA in patients who have achieved sustained virological response is associated with persistent histological abnormality.
    Wang Y; Rao H; Chi X; Li B; Liu H; Wu L; Zhang H; Liu S; Zhou G; Li N; Niu J; Wei L; Zhao J
    EBioMedicine; 2019 Aug; 46():227-235. PubMed ID: 31345785
    [TBL] [Abstract][Full Text] [Related]  

  • 20. HIV-positive men who have sex with men are at high risk of development of significant liver fibrosis after an episode of acute hepatitis C.
    Steininger K; Boyd A; Dupke S; Krznaric I; Carganico A; Munteanu M; Neifer S; Schuetze M; Obermeier M; Arasteh K; Baumgarten A; Ingiliz P
    J Viral Hepat; 2017 Oct; 24(10):832-839. PubMed ID: 28439936
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.